The Journal of allergy and clinical immunology
-
J. Allergy Clin. Immunol. · Oct 2018
Randomized Controlled TrialNemolizumab in patients with moderate-to-severe atopic dermatitis: Randomized, phase II, long-term extension study.
Nemolizumab, an anti-IL-31 receptor A mAb, improved pruritus, dermatitis, and sleep in adults with moderate-to-severe atopic dermatitis that was inadequately controlled by topical treatments in a phase II, 12-week, randomized, double-blind, placebo-controlled study (part A; NCT01986933). ⋯ Nemolizumab for up to 64 weeks was efficacious and overall well tolerated in patients with moderate-to-severe atopic dermatitis inadequately controlled by topical therapy.